Novo Nordisk Expands Weight-Loss Options with Oral Wegovy and Higher-Dose Injectable

Novo Nordisk has significantly broadened its offerings in the U.S. weight-loss market with the introduction of an oral form of its popular medication, Wegovy (semaglutide). This new daily pill provides an alternative for obesity treatment, aiming to enhance patient access and convenience.

Concurrently, the Food and Drug Administration (FDA) has given its approval to a higher-dose injectable version of Wegovy, slated for launch in April. These strategic developments are set to intensify Novo Nordisk's competitive standing in the rapidly evolving GLP-1 medication landscape.

Oral Wegovy Now Available

The oral form of Wegovy, a daily pill containing 25 milligrams of semaglutide, is now available by prescription in the U.S. Novo Nordisk touts this as the first and only oral GLP-1 medication specifically for adult weight loss, following its FDA approval in December.

The medication operates by decelerating the passage of food through the stomach and reducing appetite, thereby contributing to weight loss. Users are advised to take the daily pill 30 minutes before any other medication, food, or coffee, and it is intended for use in conjunction with a reduced-calorie diet and increased physical activity.

Pricing and Access

For self-paying patients, the initial 1.5-milligram dose of oral Wegovy is priced at $149 per month. A 4-milligram dose is also available at this price point until April 15, after which its cost will increase to $199. Without insurance, monthly costs can range between $149 and $299, depending on the dosage.

For individuals with insurance, a copay of $25 or less per month is projected, contingent on individual insurance coverage.

This contrasts with the weekly injectable version of Wegovy, which typically costs more than $300 per month without insurance. Novo Nordisk affirms that the medication is accessible through various channels, including brick-and-mortar pharmacies and telehealth partnerships, with commercial insurance coverage available from the launch day. An added benefit of the oral pill is that it is less expensive to produce and does not require refrigeration compared to its injectable counterparts.

Clinical Trials and Side Effects

Phase 3 clinical trials demonstrated promising results: participants using the oral medication experienced an average body weight reduction of approximately 14%. Those who continued treatment showed an average reduction of 17%.

These weight loss results were reported to be comparable to those achieved with injectable GLP-1 medications.

Reported side effects are similar to the injectable form, primarily including gastrointestinal issues such as nausea, diarrhea, and vomiting.

Competitive Landscape

Novo Nordisk faces stiff competition from Eli Lilly, which is currently developing its own GLP-1 pill, orforglipron. This competitor is undergoing FDA review and is anticipated to receive approval in due course. The introduction of oral Wegovy offers a crucial alternative to the predominantly injectable forms of GLP-1 treatments that have dominated the market.

A recent KFF survey indicated that approximately 1 in 8 Americans have utilized an injectable GLP-1 drug for weight loss or other medical conditions.

Higher-Dose Injectable Wegovy Approved

In a separate, yet equally significant, development, the FDA has approved a higher-dose version of Novo Nordisk's injectable Wegovy. This new 7.2-milligram dose was approved on Thursday, with Novo Nordisk anticipating its launch in April.

This strategic move aims to strengthen its competitive standing against Eli Lilly's highly effective obesity drug, Zepbound. Zepbound has previously demonstrated superior efficacy in promoting weight loss when compared to the standard 2.4-milligram dose of Wegovy.

In a phase three trial, the higher-dose injectable Wegovy led to an impressive average weight loss of 20.7% over 72 weeks for participants with obesity, significantly surpassing the approximate 15% average weight loss observed with the standard dose in earlier clinical trials.